# Cephem derivatives.

## Abstract
Described herein is a cephem derivative represented by the general formula

## Claims
1. A cephem derivative represented by the general formula wherein n stands for 1 or 2, Y stands for CH or nitrogen atom, R₁ represents a lower hydrocarbon group or a carboxyl substituted, a carbamoyl substituted, or a cyclopropyl substituted lower alkyl group, and R₂ denotes hydroxyl group, a lower alkyl group, a hydroxy substituted lower alkyl group, or carbamoyl group, or a pharmaceutically acceptable salt thereof.

## Description
This invention relates to novel cephem derivatives useful as antibacterial composition, process for the production thereof, antibacterial composition, intermediates thereof and process therefor. A number of compounds have heretofore been known as compounds, each of which contains a substituted thiadiazolylacetamido group or substituted thiazolylacetamido group at the 7 position of the cephem skeleton. For example, the compounds may be disclosed in the following publications Japanese Patent Application Laid open Nos. 11600 1980, 105689 1980, 24389 1982, 81493 1982, 4789 1983, 41887 1983, 59992 1983, 149296 1981, 102293 1977, 116492 1977, 125190 1977, 154786 1979, 192394 1982, 219292 1984, 97982 1985, 197693 1985, 231683 85, etc. Particularly, 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 1 quinuclidinio methyl 3 cephem 4 carboxylate is described in Japanese Patent Application Laid open Nos. 219292 1984, 197693 1985, and 231683 1985. However, this compound can not be practically used from a clinical point of view, because its acute toxic value LD₅₀ mouse, intravenous injection amounts to about 100 mg kg or less, and hence, the compound is very toxic. The present inventors have found that cephem derivatives, each of which has the hereinunder described group at the 3 position of the cephem skeleton, have excellent antibacterial activities, leading to completion of this invention, the group being represented by the following formula An object of this invention is therefore to provide novel compounds useful as antibacterial composition, their production process and their use as antibacterial composition. Further object of this invention is to provide novel intermediates of the above cephem derivatives and the process for the production thereof. The compounds of this invention are defined as follows A cephem derivative represented by the general formula As the lower hydrocarbon group represented by R₁ in the general formula I , may be mentioned lower alkyl groups such as methyl, ethyl, n propyl, i propyl, n butyl, t butyl and sec butyl lower alkenyl groups such as vinyl and allyl lower alkynyl groups such as propargyl and the like. While, illustrative of the carboxy substituted lower alkyl group represented by R₁ may include carboxymethyl, 2 carboxy ethyl, 3 carboxypropyl, 1 carboxyethyl, 1 carboxy 1 methylethyl, and the like. Exemplary carbamoyl substituted lower alkyl groups represented by R₁ may include carbamoylmethyl, 2 carbamoylethyl, 3 carbamoylpropyl, 1 carbamoyl 1 methylethyl, 1 carbamoylethyl and the like. Exemplary cyclopropyl substituted lower alkyl groups represented by R₁ may include cyclopropylmethyl, 2 cyclopropylethyl, and the like. As exemplary hydroxy substituted lower alkyl groups represented by R₂, may be mentioned hydroxymethyl, 2 hydroxyethyl, 1 hydroxyethyl, 3 hydroxypropyl and the like. Exemplary lower alkyl groups represented by R₂ may include methyl, ethyl, n propyl, i propyl, n butyl, t butyl, and the like. As non toxic salts of the compounds of the general formula I , may be mentioned their pharmaceutically acceptable salts, for example, their alkali metal salts such as their sodium salts and potassium salts their alkaline earth metal salts such as their calcium salts and magnesium salts their inorganic acid salts such as their hydrochlorides, hydrobromides, hydroiodides, sulfates, carbonates and bicarbonates their organic carboxylates such as their maleates, lactates and tartrates their organic sulfonates such as their methanesulfonates, benzenesulfonates and toluenesulfonates their amino acid salts such as their arginine salts, lysine salts, serine salts, aspartates and glutamates their amine salts such as their trimethylamine salts, triethylamine salts, pyridine salts, procaine salts, picoline salts, dicyclohexylamine salts, N,N dibenzylethylenediamine salts, N methylglucamine salts, diethanolamine salts, triethanolamine salts, tris hydroxymethylamino methane salts and phenethylbenzylamine salts and the like. Each of the compounds of the general formula I , which pertains to the present invention, has its syn isomer Z and anti isomer E with respect to its configuration at the following moiety The compounds of this invention can be produced by the following processes. The compounds of the general formula I and their pharmaceutically acceptable salts can be obtained by reacting a compound represented by the general formula As halogen atoms represented by X in the above general formula II , may be mentioned iodine atom, bromine atom and chlorine atom. Of these, iodine atom and bromine atom are particularly desired. The above reaction may be carried out at a reaction temperature of 10 C to 60 C or preferably 0 C to 40 C. As a reaction solvent, an anhydrous organic solvent is desired. As usable organic solvents, may be mentioned lower alkylnitriles such as acetonitrile and propionitrile halogenated lower alkyls such as chloromethane, methylene chloride and chloroform ethers such as tetrahydrofuran and dioxane amides such as N,N dimethylformamide esters such as ethyl acetate, ketones such as acetone and hydrocarbons such as benzone as well as mixed solvents thereof. As the salts of the compounds of the general formulae II and III and the protective groups for the amino group and carboxyl group in the compounds of the general formula II , those employed routinely may also be used so long as they do not impair the reaction. For example, may be mentioned formyl group, acetyl group, chloroacetyl group, dichloroacetyl group, t butoxycarbonyl group, benzyloxycarbonyl group, trityl group, p methoxybenzyl group, diphenylmethyl group and the like as protective groups for amino group and p methoxybenzyl group, p nitrobenzyl group, t butyl group, methyl group, 2,2,2 trichloroethyl group, diphenylmethyl group, pivaloyloxymethyl group and the like as protective groups for carboxyl group. And, use of a silylating agent such as bis trimethylsilyl acetamide, N methyl N trimethylsilyl acetamide or N methyl N trimethylsilyltrifluoroacetamide and the like is convenient because such a silylating agent can protect both amino and carboxyl groups at the same time. As salts of the compounds of the general formulae II and III , suitable selection may be made from their salts such as their alkali metal salts such as their sodium salts and potassium salts their alkaline earth metal salts such as their calcium salts and magnesium salts their ammonium salts their inorganic acid salts such as their hydrochlorides, hydrobromides, sulfates, carbonates, hydroiodides and bicarbonates their organic carboxylates such as their acetates, maleates, lactates and tartrates their organic sulfonates such as their methanesulfonates, benzenesulfonates and toluenesulfonates their amine salts such as their trimethylamine salts, triethylamine salts, pyridine salts, procaine salts, picoline salts, dicyclohexylamine salts, N,N dibenzylethylenediamine salts, N methylglucamine salts, diethanolamine salts, triethanolamine salts, tris hydroxymethylamino methane salts and phenethylbenzylamine salts their amino acid salts such as their arginine salts, aspartates, lysine salts, glutamates and serine salts and the like. The removal of the protective group can be carried out by any conventional processes such as hydrolysis, reduction, and the like, depending on the types of the protective groups used. The compounds of the general formula I and their pharmaceutically acceptable salts can be obtained by reacting a compound represented by the general formula The process may be carried out in accordance with any conventional N acylating reaction conditions. For example, the reaction may be performed in an inert solvent at a temperature of 50 C to 50 C, preferably 20 C to 30 C in the presence or absence of a base. Examples of the inert solvent include acetone, tetrahydrofuran, N, N dimethylformamide, N, N dimethylacetamide, dioxane, dichloromethane, chloroform, benzene, toluene, acetonitrile, or the mixed solvents thereof. An example of the base includes N, N dimethylaniline, triethylamine, pyridine, N methylmorpholine and the like. In the case where the carboxylic acids COOH represented by the general formula V are used in the process according to the present invention, the reaction is preferably carried out in the presence of a condensation agent such as N, N dicyclohexylcarbodiimide, N, N diethylcarbodiimide, N cyclohexyl N morpholinoethylcarbodiimide, trialkyl phosphite, ethyl polyphosphate, p toluenesulfonic acid chloride and the like. Furthermore, in the case where such a reactive derivative at the carboxyl group in the general formula V is used, an example of the reactive derivative includes acid halides such as acid chloride, acid bromide and the like symmetric acid anhydrides mixed acid anhydrides with carboxylic acid such as ethyl chlorocarbonate, trimethylacetic acid, thioacetic acid, diphenylacetic acid and the like active esters with 2 mercaptopyridine, cyanomethanol, p nitrophenol, 2, 4 dinitrophenol, pentachlorophenol and the like and active acid amides with saccharin and the like. As the protective groups for COO of the compound of the general formula IV , there can be similarly used the groups which were mentioned as the protective groups for carboxyl group of the compound of the aforesaid general formula II . And, as the protective group for amino group of the compound of the general formula V , there can be used the groups which were illustrated as the protective groups for amino group of the compound of the above mentioned general formula II . These protective groups can be removed by any conventional manners, such as hydrolysis, reduction, and the like, depending on the types of the protective groups used. Besides, for instance, as the salts of the compounds of the formulae IV and V , there may be suitably selected from the salts which were illustrated as the salts of the compounds of the general formulae II and III . The novel compounds represented by the general formula Examples of R3 being the protective group for the amino group in the compounds represented by said general formula VI include those employed usually in this field, for example, substituted or unsubstituted lower alkanoyl groups, such as formyl, acetyl, chloroacetyl, dichloroacetyl, propionyl, phenylacetyl, 2 thienylacetyl, 2 furylacetyl, phenoxyacetyl and the like substituted or unsubstituted lower alkoxycarbonyl groups such as benzyloxycarbonyl, t butoxycarbonyl, p nitrobenzyloxycarbonyl and the like substituted lower alkyl groups such as trityl, p methoxybenzyl, diphenylmethyl and the like and substituted silyl groups such as trimethylsilyl, t butyldimethylsilyl and the like. Examples of R₅ being the protective group for the carboxyl group include those employed usually in this field, for example, substituted or unsubstituted lower alkyl groups such as methyl, ethyl, propyl, t butyl, 2,2,2 trichloroethyl, valeryloxymethyl, pivaloyloxymethyl, p nitrobenzyl, p methoxybenzyl, diphenylmethyl and the like and substituted silyl groups such as trimethylsilyl, t butyldimethylsilyl and the like. Examples of the anion in A include halogen ions such as chloro ion, bromo ion, iodo ion and the like and inorganic acid ions such as sulfuric acid ion, nitric acid ion and the like. An example of salts of the compounds represented by the general formula VI includes inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, carbonate, bicarbonate and the like organic carboxylates such as, acetate, maleate, lactate, tartrate, trifluoroacetate and the like organic sulfonates such as methanesulfonate, benzenesulfonate, toluenesulfonate and the like and amino acid salts such as aspartate, glutamate and the like. The compounds represented by the general formula VI can be produced in accordance with the following process. A compound represented by the general formula When the case wherein Z in the general formula VII represents a halogen atom, the above reaction may be carried out in an inert solvent such as acetone, tetrahydrofuran, N, N dimethylformamide, methylene chloride, chloroform, acetonitrile, and the like at a reaction temperature of 10 C to 50 C. When the case wherein Z in the general formula VII represents a lower alkanoyloxy group, the above reaction may be carried out in an inert solvent such as achloroform, methylene chloride, tetrahydrofuran, N, N dimethylformamide, dioxane, acetone, and the like in the presence of iodotrimethylsilane at a reaction temperature of 20 C to 60 C. The removal of protective groups may be achieved in accordance with a conventional procedure such as hydrolysis, reduction and the like, depending upon type of the protective group used. Furthermore, the reduction of sulfoxide may be carried out by using such a conventional reduction reagent, for example, phosphorus trichloride, and the like. An example of Z being the halogen atom in the compound represented by the general formula VII includes chlorine, bromine, or iodine atom. An example of Z being the lower alkanoyloxy group includes acetyloxy, propionyloxy, and the like. An example of R₆ being the protective group for carboxyl group includes those enumerated in the description for said R₅. Furthermore, any salt which does not inhibit said reaction may be used as the salts of the compounds represented by the general formulae VII and III , and these salts may be suitably selected from the group consisting of, for example, alkali metal salts such as sodium, potassium and the like salts alkaline earth metal salts such as calcium, magnesium and the like salts ammonium salts inorganic acid salts such as hydrochloride, sulfate, carbonate, bicarbonate,hydrobromide, hydroiodide, and the like organic carboxylates such as acetate, maleate, lactate, tartrate, trifluoroacetate and the like organic sulfonates such as methanesulfonate, benzenesulfonate, toluenesulfonate and the like amine salts such as trimethylamine, triethylamine, pyridine, procaine, picoline, dicyclohexylamine, N, N dibenzylethylenediamine, N methylglucamine, diethanolamine, triethanolamine, tris hydroxymethylamino methane and the like salts and amino acid salts such as alginate, aspartate, glutamate and lysine, serine or the like salt. The compounds of this invention showed strong antibacterial activities against both gram positive and gram negative bacteria. In addition, in the case of the following compounds, all of their acute toxicity levels LD₅₀ mouse, intravenous injection were found to be more than 3 g kg. When using the compounds of this invention as antibacterial compositions, their dosages are 2 to 300 mg kg day or preferably 10 to 100 mg kg day. The antibacterial composition may be administered orally in the form of powder, granules, capsules, tablets and the like,or parenterally in the form of pareteral solutions, suppositories and the like. These compositions may be prepared in usual manner, using an effective amount of the compound of this invention and pharmaceutically acceptable excipients. By the way, the following nomenclature is used in the present invention. The present invention will be described in further detail by the following Experiments and Examples. Conc. sulfuric acid 12 mℓ was added to an ethanol solution 50 mℓ of 1 benzyl 4 cyano 4 hydroxypiperidine hydrochloride 10 g and the resulting mixture was heated at 130 C for 24 hours in a sealed tube. After concentration of the reaction mixture, ice water was added to the concentrate. The resulting mixture was added with an aqueous solution of sodium hydrogencarbonate. After adjusting the thus obtained solution to pH 7.0, it was extracted with diethyl ether. The extract was washed with brine and then added with anhydrous sodium sulfate to dry same. The solvent was distilled off to obtain the intended product 9.7 g . To a diethyl ether suspension 0.5 ℓ of lithium aluminum hydride 19.4 g , a diethyl ether solution 0.5 ℓ of the compound 44.6 g obtained in the above procedure 1 was added dropwise under ice cooling. After completion of the dropwise addition, the resulting mixture was stirred for 1.5 hrs. After addition of ethyl acetate 100 mℓ and saturated aqueous sodium sulfate solution 100 mℓ to the reaction mixture, the resulting mixture was filtered through Celite trade mark . The residue was washed with tetrahydrofuran. The filtrate and washing were combined together, followed by their concentration under reduced pressure. The residue was then purified by alumina column chromatography eluent chloroform, 5 methanol chloroform, and 20 methanol chloroform to obtain the desired product 31.5 g . To a pyridine solution 120 mℓ of the compound 11.3 g obtained in the above procedure 2 , p toluenesulfonyl chloride 10.7 g was added at 30 C. The resulting mixture was heated to 4 C, at which it was stirred for 15 hours. The reaction mixture was concentrated under reduced pressure and the thus obtained residue was dissolved in a small amount of ice water. After adding 2N aqueous potassium hydroxide solution 82 mℓ to the above prepared solution, the resulting solution was extracted with benzene. Anhydrous potassium carbonate was added to the extract to dry same. After refluxing the solution for 9 hours, it was cooled to room temperature. The resulting precipitate was collected by filtration and then washed with absolute benzene to obtain the desired product 16.5 g . Added to a methanol solution 300 mℓ of the compound 16.5 g obtained in the above procedure 3 was 10 palladium carbon 50 water content 3.3 g , followed by stirring for 3 hours in a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. Saturated aqueous potassium carbonate solution was added to the residue, followed by extraction with chloroform. After adding anhydrous potassium carbonate to the extract to dry same, the thus dried extract was concentrated under reduced pressure to obtain the desired product 4.0 g . 1.70 4H,m , 2.41 2H,s , 2.75 2H,m , 3.16 2H,m . 7β Z 2 2 Aminothiazol 4 yl 2 methoxyimino acetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 240 mg was suspended in methylene chloride 4 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 330 µℓ . The resulting mixture was stirred at room temperature for 30 minutes. After ice cooling, iodotrimethylsilane 200 µℓ was added to the solution, and the resulting mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 3 mℓ , followed by an addition of tetrahydrofuran 60 µℓ . The thus obtained solution was added with 4 hydroxy 1,4 methylenepiperidine 72 mg and the resulting mixture was stirred at room temperature for 2 hours. Methanol 0.3 mℓ was then added to the reaction mixture and the resulting mixture was stirred for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was dissolved in a 7 1 mixed solvents of acetone and water. The resulting solution was purified by silica gel column chromatography eluent 9 1 and 7 1 mixed solvents of acetone and water to obtain the desired product 39 mg . 7β Z 2 5 Amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 319 mg was suspended in methylene chloride 4 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 877 µℓ . The resulting mixture was stirred at room temperature for 1 hour. After ice cooling, iodotrimethylsilane 268 µℓ was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 3.6 mℓ . The thus obtained solution was added with 4 hydroxy 1,4 methylenepiperizine 71 mg and the resulting mixture was stirred for 2 hours with ice cooling. Methanol 0.3 mℓ was then added to the reaction mixture and the resulting mixture was stirred for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was dissolved in a 7 1 mixed solvents of acetone and water. The resulting solution was purified by silica gel column chromatography eluent 7 1 and 5 1 mixed solvents of acetone and water to obtain the desired product 29 mg . 7β Z 2 Aminothiazol 4 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 977 mg was suspended in methylene chloride 16 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 1350 µℓ . The resulting mixture was stirred at room temperature for 1 hour. After ice cooling, iodotrimethylsilane 810 µℓ was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 12 mℓ , followed by an addition of tetrahydrofuran 240 µℓ . The thus obtained solution was added with 4 hydroxyquinuclidine 300 mg and the resulting mixture was stirred at room temperature for 1.5 hours. Methanol 1.2 mℓ was then added to the reaction mixture and the resulting mixture was stirred for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was dissolved in a 7 1 mixed solvents of acetone and water. The resulting solution was purified by silica gel column chromatography eluent 7 1 mixed solvent of acetone and water to obtain the desired product 38 mg . 7β Z 2 5 Amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 486 mg was suspended in methylene chloride 9 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 980 µℓ . The resulting mixture was stirred at room temperature for 1 hour. After ice cooling, iodotrimethylsilane 410 µℓ was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 6 mℓ , followed by an addition of tetrahydrofuran 130 µℓ . The resulting solution was added with 4 hydroquinuclidine 150 mg and the resulting mixture was stirred at room temperature for 1 hour. Methanol 0.6 mℓ was then added to the reaction mixture and the resulting mixture was stirred for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was purified by silica gel column chromatography eluent 9 1 mixed solvents of acetone and water to obtain the desired product 13 mg . 7β Z 2 2 Aminothiazol 4 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 240 mg was suspended in methylene chloride 4 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 330 µℓ . The resulting mixture was stirred at room temperature for 30 minutes. After ice cooling, iodotrimethylsilane 200 µℓ was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was then concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 3 mℓ , followed by an addition of tetrahydrofuran 60 µℓ . The resulting solution was added with 4 carbamoylquinuclidine 98 mg and the resulting mixture was stirred at room temperature for 2 hours. Methanol 0.3 mℓ was then added to the reaction mixture and the resulting mixture was stirred at room temperature for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was dissolved in a 7 1 mixed solvent of acetone and water. The thus obtained solution was purified by silica gel column chromatography eluent 7 1 mixed solvents of acetone and water to obtain the desired product 53 mg . 7β Z 2 5 Amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 790 mg was suspended in methylene chloride 10 mℓ , followed by an addition of N methyl N trimethylsilyl trifluoroacetamide 2.1 mℓ . The resulting mixture was stirred at room temperature for 1 hour. After ice cooling, iodotrimethylsilane 660 µℓ was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was concentrated under reduced pressure to obtain the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid. The silylated derivative was dissolved in acetonitrile 9 mℓ , followed by an addition of 4 carbamoylquinuclidine 240 mg . The resulting mixture was stirred for 1 hour with ice cooling. Methanol 0.6 mℓ was then added to the reaction mixture and the resulting mixture was stirred for 15 minutes. The resulting precipitate was collected by filtration and then washed with acetonitrile. The precipitate was dissolved in 30 ethanol. Subsequent to its concentration under reduced pressure, the residue was dissolved in 7 1 mixed solvents of acetone and water. The solution was purified by silica gel column chromatography eluent 7 1 and 5 1 mixed solvents of acetone and water to obtain the desired product 326 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 carboxymethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 carboxymethoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 500 mg , N methyl N trimethylsilyl trifluoroacetamide 1.23 mℓ and iodotrimethylsilane 780 µℓ . The silylated derivative was reacted with 4 hydroxy 1,4 methylenepiperidine 90 mg to obtain the desired product 113 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 2 aminothiazol 4 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 240 mg , N methyl N trimethylsilyl trifluoroacetamide 330 µℓ and iodotrimethylsilane 300 µℓ . The silylated derivative was reacted with 4 hydroxymethylquinuclidine 89 mg to obtain the desired product 6 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 propargyloxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 2 aminothiazol 4 yl 2 propargyloximinoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 290 mg , N methyl N trimethylsilyl trifluoroacetamide 380 µℓ and iodotrimethylsilane 230 µℓ . The silylated derivative was reacted with 4 carbamoylquinuclidine 112 mg to obtain the desired product 10 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 2 aminothiazol 4 yl 2 carbamoylmethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 2 aminothiazol 4 yl 2 carbamoylmethoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 110 mg , N methyl N trimethylsilyl trifluoroacetamide 140 µℓ and iodotrimethylsilane 180 µℓ . The silylated derivative was reacted with 4 carbamoylquinuclidine 41 mg to obtain the desired product 5 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 ethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 ethoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 300 mg , N methyl N trimethylsilyl trifluoroacetamide 600 µℓ and iodotrimethylsilane 500 µℓ . The silylated derivative was reacted with 4 carbamoylquinuclidine 118 mg to obtain the desired product 62 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 1 carboxy 1 methylethoxy iminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 1 carboxy 1 methoxyethoxy iminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 530 mg , N methyl N trimethylsilyl trifluoroacetamide 820 µℓ and iodotrimethylsilane 390 µℓ . The silylated derivative was reacted with 4 carbamoylquinuclidine 186 mg to obtain the desired product 100 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 carboxymethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 carboxymethoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 500 mg , N methyl N trimethylsilyl trifluoroacetamide 1.23 µℓ and iodotrimethylsilane 780 µℓ . The silylated derivative was reacted with 4 carbamoylquinuclidine 142 mg to obtain the desired product 36 mg . Similar to Examples 1 6, the silylated derivative of 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylic acid was obtained from 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 460 mg , N methyl N trimethylsilyl trifluoroacetamide 640 µℓ , and iodotrimethylsilane 390 µℓ . The silylated derivative was reacted with 4 hydroxylmethylquinuclidine 142 mg to obtain the desired product 8 mg . p Methoxybenzyl 7β Z 2 5 amino 1,2,4 thiadiazol 3 yl 2 methoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylate 700 mg was dissolved in a mixed solution of ethyl acetate 50 ml and methanol 1 mℓ . After the whole was ice cooled, a solution of ethyl acetate 2.8 mℓ of 4 methyl quinuclidine 114 mg was added thereto, and the mixture was stirred for 15 minutes. The resulting precipitate was recovered by filtration, followed by wasing with ethyl acetate to obtain p methoxybenzyl 7β Z 2 5 amino 1,2,4 thiaidazol 3 yl 2 methoxyiminoacetamido 3 4 methyl 1 quinuclidinio methyl 3 cephem 4 carboxylate iodide 770 mg . This compound 770 mg was suspended in methylene chloride 8 mℓ . After ice cooling, anisole 510 µℓ and trifluoroacetic acid 730 µℓ were added thereto. The mixture was stirred for 4 hours, followed by stirring for an additional 2.5 hours at a room temperature. The resulting reaction solution was dropped in diisopropyl ether 30 mℓ , and the resulting precipitate was collected by filtration. The precipitate dissolved in water 5 mℓ . The solution was adjusted to pH of 5.0 by the addition of sodium hydrogencarbonate. The mixture was subjected to a reversed phase silica gel column chromatography eluent water 5 methanol solution for purification, to obtain the desired product 27 mg . p Methoxybenzyl 7β Z 2 5 t butoxycarboxamido 1,2,4 thiadiazol 3 yl 2 cyclopropylmethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylate 450 mg was dissolved in ethyl acetate 30 mℓ . After ice cooling, there was added a mixted solution of methanol 1 mℓ and ethyl acetate 5 mℓ of 4 carbamoylquinuclidine 80 mg , and the whole was stirred for 30 minutes. The formed precipitate was collected by filtration, followed by washing with ethyl acetate to obtain p methoxybenzyl 7β Z 2 5 t butoxycarboxamido 1,2,4 thiadiazol 3 yl 2 cyclopropylmethoxyiminoacetamido 3 4 carbamoyl 1 quinuclidinio methyl 3 cephem 4 carboxylate iodide 290 mg . This compound 290 mg was dissolved in formic acid 6 mℓ , and the resulting solution was stirred for a day at a room temperature. To the reaction solution added acetone 10 mℓ , diisopropyl ether 30 mℓ and n hexane 50 mℓ . The formed precipitate was filtered off, and the filtrate was concentrated under a reduced pressure. The residue was dissolved in a water methanol solution 10 mℓ , and the solution was adjusted to pH of 5.5 by the addition of sodium hydrogencarbonate. The resulting solution was concentrated, followed by purifying through reversed phase silica gel column chromatography eluent water 5 methanol solution to obtain the desired product 19 mg . Similar to Example 16, p methoxybenzyl 7β Z 2 5 t butoxycarboxamido 1,2,4 thiadiazol 3 yl 2 cyclopropylmethoxyiminoacetamido 3 iodomethyl 3 cephem 4 carboxylate 450 mg was reacted with 4 hydroxymethylquinuclidine 73 mg to obtain p methoxybenzyl 7β Z 2 5 t butoxycarboxamido 1,2,4 thiadiazol 3 yl 2 cyclopropylmethoxyiminoacetamido 3 4 hydroxymethyl 1 quinuclidinio methyl 3 cephem 4 carboxylate 310 mg , followed by removing a protective group by means of formic acid to obtain the desired product 23 mg . 7β Formamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 1.2 g was suspended in methylene chloride 12 mℓ , and then N methyl N trimethylsilyl trifluoroacetamide 815 µℓ was added thereto and stirred for 30 minutes. After cooling the mixture with ice, iodotrimethylsilane 1.25 mℓ was added thereto and stirred for 5 minutes, thereafter the temperature of the mixture was returned to a room temperature, and the mixture was stirred for another 15 minutes. Solvent was distilled away under reduced pressure from the resulting solution, and the residue was dissolved in acetonitrile 12 mℓ . 4 Carbamoylquinuclidine 616 mg was added to the solution under ice cooling and stirred for 1 hour. To the reaction solution was added methanol 3 mℓ and further diethyl ether 300 mℓ , and the resulting precipitate was filtered. The precipitate was purified by means of silica gel column chromatography eluent acetone water 7 1 and 5 1 to obtain the desired product 140 mg . 7β Tritylamino 3 acetoxymethyl 3 cephem 4 carboxylic acid 2.4 g was dissolved in methylene chloride 24 mℓ , and then N methyl N trimethylsilyl trifluoroacetamide 960 µℓ was added thereto and stirred for 30 minutes. After cooling the mixture with ice, iodotrimethylsilane 720 µℓ was added thereto and stirred for 5 minutes, thereafter the temperature of the mixture was returned to a room temperature, and the mixture was stirred for another 15 minutes. Solvent was distilled away under reduced pressure from the resulting solution, and the residue was dissolved in acetonitrile 12 mℓ . 4 Carbamoylquinuclidine 756 mg was added to the solution under ice cooling and stirred for 1 hour. To the reaction solution was added methanol 3.2 mℓ and then diethyl ether 240 mℓ , and the resulting precipitate was filtered. The precipitate was purified by means of silica gel column chromatography eluent acetone water 7 1 , 5 1 , and 3 1 to obtain the desired product 207 mg . 7β 2 Thienylacetamido 3 acetoxymethyl 3 cephem 4 carboxylic acid 6.0 g was suspended in methylene chloride 60 mℓ , and then N methyl N trimethylsilyl trifluoroacetamide 3.08 mℓ was added thereto and stirred for 30 minutes. After cooling the mixture with ice, iodotrimethylsilane 4.73 mℓ was added thereto and stirred for 5 minutes, thereafter the mixture was further stirred at a room temperature for another 15 minutes. The resulting solution was concentrated under reduced pressure, and the residue was dissolved in acetonitrile 60 mℓ . After ice cooling the resulting solution, 4 carbamoylquinuclidine 2.3 g was added to the solution and stirred for 1 hour. To the reaction solution was added methanol 6 mℓ , and then diethyl ether 600 mℓ was dropped thereto. After stirring the mixture for 1 hour, the resulting precipitate was filtered. The precipitate was purified by means of silica gel column chromatography eluent acetone water 7 1 and and 5 1 to obtain the desired product 700 mg . The compound 130 mg prepared in Experiment 2 was suspended in methanol 5 mℓ , and concentrated hydrochloric acid 0.52 mℓ was added to the suspension at room temperature and stirred for 4 hours. The reaction mixture was concentrated under reduced pressure and crystallized by means of ethyl ether methanol, whereby the desired product 115 mg was obtained. The compound 100 mg prepared in Experiment 3 was suspended in 50 formic acid 5 mℓ , and stirred at a room temperature for 3.5 hours. To the suspension was added water 20 mℓ and insoluble matter was filtered off, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1 N hydrochloric acid 1 mℓ , and propanol 5 mℓ and diethyl ether 10 mℓ was added thereto. The precipitate was filtered, washed with n hexane, and then dried, whereby the desired product 45 mg was obtained. The compound 600 mg prepared in Experiment 4 was suspended in methylene chloride 30 mℓ , N,N dimethylaniline 1.24 mℓ and chlorotrimethylsilane 465 µℓ were added thereto, and mixture was stirred at 30 C for 3 hours. Then, the reaction mixture was cooled to 25 C, thereafter phosphorus pentachloride 1.27 g was added thereto, and the mixture was stirred for 1 hour. To the solution was added an ice cooled solution of 1,3 butanediol 1.3 mℓ in methylene chloride 25 mℓ , and the mixture was stirred at the same temperature for 10 minutes. The reaction mixture was warmed to 0 C and stirred further for 40 minutes, and then the resulting precipitate was filtered. The precipitate was dissolved in methanol 7 mℓ , and the insoluble matter was filtered off. Thereafter methylene chloride 20 mℓ and diethyl ether 20 mℓ were added to the filtrate, so that the precipitate was filtered to obtain the desired product 30 mg . t Butyl 7β amino 3 bromomethyl 3 cephem 4 carboxylate 1 oxide hydrobromide 600 mg was dissolved in N,N dimethylformamide 6 mℓ , and 4 carbamoylquinuclidine 456 mg was added thereto, and the mixture was stirred in argon gas stream at a room temperature for 14 hours. To the reaction solution was added diethyl ether 120 mℓ , the resulting precipitate was filtered and washed with n hexane, whereby the desired product 580 mg was obtained. The compound 570 mg prepared in Experiment 8 was dissolved in N,N dimethylformamide 10 mℓ , phosphorus trichloride 500 µℓ was added to the solution at 25 C and stirred for 30 minutes. To the reaction solution were added diethyl ether 50 mℓ , so that the separated oil was taken out and washed with diethyl ether, thereafter the resulting solid was dried under reduced pressure to obtain the desired product 164 mg . To the compound 150 mg prepared in Experiment 9 was added formic acid 1.5 mℓ and concentrated hydrochloric acid 0.15 mℓ under ice cooled condition, and the mixture was stirred for 4 hours, thereafter concentrated under reduced pressure. The residue was dissolved in ice water 5 mℓ and neutralized with sodium bicarbonate. The resulting product was purified with reversed phase silica gel column chromatography eluent water to obtain the desired product 60 mg . p Methoxybenzyl 7β phenylacetamido 3 chloromethyl 3 cephem 4 carboxylate 980 mg was suspended in acetone 20 mℓ , and sodium iodide 362 mg was added to the suspension and stirred at a room temperature for 1 hour. To the resulting suspension were added 4 carbamoylquinuclidine 313 mg under ice cooled condition, and the mixture was stirred for 2 hours. The reaction mixture was filtered, and diethyl ether 70 mℓ was added to the filtrate. The deposited solid was filtered to obtain the desired product 500 mg . To ethyl acetate solution 465 mℓ of p methoxybenzyl 7β formamido 3 iodomethyl 3 cephem 4 carboxylate 9.3 g added dropwise over 1 hour under stirring while ice cooling a mixed solution 176 mℓ of methanol and ethyl acetate 1 4 v v of 4 carbamoyl quinuclidine 2.94 g . After stirring for 30 minutes, the resulting precipitate was collected by filtration, followed by washing with ethyl acetate and then diisopropyl ether to obtain the desired product 12.0 g . The compound 11.8 g obtained in the preceding Experiment 12 was dissolved in ice cooled formic acid 50 mℓ , followed by stirring for 10 hours at a room temperature. The reaction solution was subjected to a filtration, and the filtrate was added dropwise into acetone 100 mℓ . To the resulting solution added dropwise further diisopropyl ether 200 mℓ . The formed precipitate was collected by filtration, followed by washing with acetone. The precipitate was dissolved in dimethyl formamide 30 mℓ . The solution was added dropwise in acetone 150 mℓ . The formed precipitate was collected by filtration, followed by washing with acetone and diisopropyl ether respectively. Thereafter, the solid was dried under a reduced pressure to obtain the desired product 6.66 g . A mixture consisting of 2 5 amino 1,2,4 thiadizaol 3 yl Z 2 methoxyiminoacetic acid 46 mg , 1 hydroxy 1H benzotriazole hydrate 35 mg , N, N dicyclohexylcarbodiimide 52 mg , and N, N dimethylformamide 1 mℓ was stirred at a room temperature for 3 hours, then the mixture was filtered, and the filtrate was cooled to 0 C. The resulting solution was added to an ice cooled solution of 7β amino 3 4 carbamoyl 1 quinuclidinio methyl 3 cephem 4 carboxylic acid hydrochloride 100 mg , N, N dimethylformamide 2 mℓ , and N, N dimethylaniline 72 µℓ . After stirring the mixed solution at a room temperature for 14 hours, the reaction mixture was filtered, and the filtrate was dropped into diethyl ether 100 mℓ , while stirring the mixture. The deposited precipitate was filtered out and washed with diethyl ether. To the washed precipitate was added water 10 mℓ , and insoluble matter was filtered off. The resulting filtrate was purified with reversed phase silica gel column chromatography to obtain the desired product 3 mg . 7β Amino 3 4 carbamoyl 1 quinuclidinio methyl 3 cephem 4 carboxylic acid hydrochloride 2 g was dissolved in acetonitrile water 1 1 mixed solution 40 mℓ , and triethylamine 2.08 mℓ was added to the solution. The resulting solution was cooled with ice and 2 5 amino 1,2,4 thiadiazol 3 yl Z 2 methoxyiminoacetylchloride 2.55 g was added thereto, and the mixture was stirred for 50 minutes. The reaction solution was added to ethanol 200 mℓ , the deposited solid was filtered, and the solid was washed with ethanol and isopropyl ether, whereby the desired product 450 mg was obtained. Infrared absorption spectrum as well as NMR spectrum of the product coincided with those of Example 18. The compounds of the following Examples 20 28 were synthesized in accordance with the same manner as those of Examples 18 and 19.